Veeva Systems reported fiscal 2027 second-quarter revenue of $927.963 million, up 18% from $789.1 million a year earlier and above the $905.28 million analyst estimate. Adjusted diluted earnings per share were $2.35, exceeding the $2.22 consensus, while subscription revenue rose 16% to $766.8 million. Results surpassed both company guidance and analyst expectations. Veeva raised its fiscal 2027 revenue outlook to $3.682 billion-$3.687 billion and its adjusted earnings-per-share forecast to $9.05-$9.21, above the $9.06 analyst consensus. The company is actively reducing its share count through a $2 billion buyback program that supports earnings per share growth. Shares rose 20% to close at $294.54, while a separate post-earnings report cited an 11.5% premarket gain to $273.00. At least five firms raised price targets, including Piper Sandler to $320, Needham to $310, Truist Securities to $305, Evercore ISI Group to $250 and Morgan Stanley to $275. Eli Lilly and Biogen selected Vault CRM, bringing the number of top-20 biopharmaceutical companies using or committed to the platform to 12. CEO Peter Gassner said Vault CRM had its best quarter ever and that Veeva Falcon accelerated rapidly, describing artificial intelligence as opening a new chapter for the company and the life-sciences industry. Veeva's Nov. 5 investor day is expected to provide further detail on its AI strategy.